Zai Lab Ltd is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include three drug candidates with greater China rights and three drug candidates with global rights. The greater China rights drug candidates include Niraparib (ZL-2306), Omadacycline (ZL-2401) and ZL-2301. The global rights drug candidates include Fugan (ZL-3101), ZL-2302 and ZL-1101.

Biotechnology

Zai Lab

The South San Francisco office focuses on clinical operations, research, and communications in the biotechnology sector.

South San Francisco

The San Diego office focuses on advanced research and development in biologics and cancer biology.

San Diego

The Cambridge office focuses on drug discovery and development, emphasizing clinical and legal aspects of biopharmaceutical innovation.

People (4)

Jobs (0)

Other offices